# A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

> **NCT05708950** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Kineta Inc.** · enrollment: 314 (estimated)

## Conditions studied

- Cancer
- Solid Tumor
- Melanoma
- Carcinoma
- Sarcoma
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colo-rectal Cancer
- Uterine Cancer
- Pancreatic Cancer
- Gastric Cancer
- Esophageal Cancer
- Thyroid Cancer
- Ovarian Cancer
- Kidney Cancer
- Head and Neck Cancer

## Interventions

- **DRUG:** KVA12123 - Dose Escalation
- **DRUG:** KVA12123 Plus Pembrolizumab - Dose Escalation
- **DRUG:** KVA12123 - Dose Expansion
- **DRUG:** KVA12123 Plus Pembrolizumab - Dose Expansion

## Key facts

- **NCT ID:** NCT05708950
- **Lead sponsor:** Kineta Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-03
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 314 (ESTIMATED)
- **Last updated:** 2023-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05708950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05708950, "A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05708950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*